Combining the anticancer drugs enfortumab vedotin and pembrolizumab (EV+P) led to significantly improved survival rates among patients with advanced urothelial cancer (the most common type of bladder cancer) compared with standard chemotherapy, according to results of a large international clinical trial involving 185 sites, including the Johns Hopkins Kimmel Cancer Center’s Greenberg Bladder Cancer Institute, in 25 countries.
Tag: urothelial cancer
New Treatment for Urinary Tract Cancer Could Prevent Kidney Dialysis, Transplant
UC San Diego Health is now offering a new treatment for patients with low-grade upper tract urothelial cancer that could safely avoid removal of the entire kidney, which may prevent the need for dialysis or kidney transplant in the future.
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association (AUA) annual meeting in May.